ProCE Banner Activity

TROPiCS-03 Phase II Basket Trial: Sacituzumab Govitecan as Second-line Therapy for Extensive-Stage Small-Cell Lung Cancer

Conference Coverage

In a multicohort basket trial, sacituzumab govitecan showed activity in patients with extensive-stage small-cell lung cancer previously treated with first-line platinum-based chemotherapy and anti‒PD-1/PD-L1 therapy.

Released: October 24, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc